Radiation and drug combo shows promise for tough liver cancers

NCT ID NCT07668570

Not yet recruiting Disease control Sponsor: Hebei Medical University Fourth Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a combination of targeted radiation (SBRT) and an experimental drug called QL1706 in 36 adults with advanced liver cancer that has worsened after one prior treatment. The radiation is given to liver tumors over five sessions, followed by QL1706 infusions every three weeks. The goal is to see if this approach can shrink tumors and control the disease safely.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Stereotactic body radiation therapy (SBRT) and QL1706 (Iparomlimab and Tuvonralimab injection)
What this could lead to: If successful, this combination could offer a new second-line treatment option for liver cancer patients, potentially shrinking tumors and extending survival.
What could go wrong: This is a small, early-phase study with only 36 participants, so results may not apply to everyone. Side effects from radiation and the drug are possible, and the treatment may not work for all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HCC - HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HCC - HEPATOCELLULAR CARCINOMA

More trials for these conditions

Other studies related to the condition(s) this trial covers.